U.S. Triptorelin Market to Surpass US$ 278.4 Million by 2030 - Coherent Market Insights

U.S. Triptorelin Market, by Product Type (Triptorelin Pamoate, Triptorelin Acetate, and Triptorelin Embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, and Central Precocious Puberty), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), was valued at US$ 171.7 million in 2022 and is expected to exhibit a CAGR of 5.5% during the forecast period (2022-2030).

Increasing product approvals from the regulatory authorities, is expected to drive the growth of the U.S. triptorelin market, over the forecast period. For instance, in 2017, Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for Triptodur (triptorelin) six month formulation, an extended release injectable suspension, which is indicated for the treatment of pediatric patients which are in the age of 2 years and older and are suffering from central precocious puberty (CPP). CPP is a genetic condition which occurs due to the mutations in the MKRN3 gene. In this condition, a child shows signs of puberty sooner than normal i.e. before the age of eight in girls and nine in boys.

Furthermore, in the same year, Triptodur (triptorelin) six month formulation was developed by Debiopharm International SA and was manufactured in Switzerland by Debiopharm Research & Manufacturing SA. In the year 2015, Arbor Pharmaceuticals, LLC, acquired the exclusive U.S. commercial rights to Triptorelin 6-month for the treatment of CPP.

U.S. Triptorelin Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic is expected to drive the growth of the U.S. triptorelin market over the forecast period. After the spread of coronavirus, major companies operating in U.S. triptorelin market indulged in the transportation of the COVID-19 patients to the countries where proper equipment are present. Moreover, there has been an increase in the number of COVID-19 patients, which is also expected to contribute to the growth of the market. For instance, according to the U.S.an Centers for Disease Control and Prevention (CDC), the following table shows the number of patients suffering from COVID-19 infections among the different U.S.an countries

Increasing awareness of the drug triptorelin by various organizations is expected to increase the growth of the U.S. triptorelin market over the forecast period. For instance, Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer center, updated the information regarding the drug triptorelin and the treatment of prostate cancer using triptorelin on the organizations website. This will increase the awareness about the drug triptorelin among the physicians and patients for the treatment of prostate cancer.

Browse 34 Market Data Tables and 28 Figures spread through 164 Pages and in-depth TOC on U.S. Triptorelin Market, by Product Type (Triptorelin Pamoate, Triptorelin Acetate, and Triptorelin Embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, and Central Precocious Puberty), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

To know the latest trends and insights prevalent in the U.S. triptorelin market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-triptorelin-market-4941

Increasing prevalence of GnRH-dependent central precocious puberty (CPP) is expected to drive the growth of the market over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI): 2018, GnRH-dependent CPP is defined by ‘pubertal development occurring before the age of 8 years in girls and 9 years in boys’. GnRH-dependent CPP condition is mostly characterized by early pubertal changes such as breast development, etc. in girls and increased testicular and penile growth in boys, reduced adult height due to premature fusion of the growth plates, etc. this rare condition is observed in 1 out of every 5,000 to 10,000 children. Moreover, GnRH-dependent CPP is more common in girls than in boys, with a female: male ratio estimated to be between 3:1 and 23:1.

Key Takeaways of the U.S. Triptorelin Market:

• The U.S. triptorelin market is expected to exhibit a CAGR of 5.5% over the forecast period (2022-2030).
• Market players are indulged in inorganic activities such as partnerships, in order to commercialize the drug triptorelin in the U.S., this is expected to drive the growth of the U.S. triptorelin market, over the forecast period. For instance, in 2019, Debiopharm Group, a Swiss-based global biopharmaceutical company, entered into an agreement with Allergan Inc. in order to commercialize of Trelstar in the U.S. and Canada. Under this agreement, Debiopharm Group, was engaged in seeking new licensees in the Territory while Allergan Inc., supported the company for the commercialization of the product until new partners are secured.
• Some of the major players operating in the U.S. triptorelin market include Ipsen USA, Bachem Americas, Inc., Ferring Pharmaceuticals USA, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Watson Laboratories, Inc.